PTC Therapeutics' stock surged 5.57% during the trading session, reflecting strong investor optimism following the company's latest financial results.

The biopharmaceutical company reported first-quarter 2026 revenue of $273 million, significantly beating analyst consensus estimates of approximately $225 million. Additionally, the company posted an adjusted loss per share of $0.03, which was a substantial improvement over the expected loss of $0.48 per share.

Investor sentiment was further bolstered by the company's decision to raise its full-year 2026 guidance. PTC Therapeutics now expects total revenue to be in the range of $1.08 billion to $1.18 billion, up from previous estimates and above the consensus forecast. The strong quarterly performance was primarily driven by a 47% year-over-year increase in product revenue, fueled by the successful launch of its drug Sephience.